



**Supplementary Figure 1.** Immunohistochemistry analysis showing the effect of GV1001 on the expression of intracellular signaling proteins, a neuronal nuclear marker (neuronal nuclei [NeuN])–positive cells, and SRY-box transcription factor 2 (SOX2; a neural stem cell marker)–positive cells in per-infarct regions of rats. In GV1001-treated groups, phosphorylated Akt (pAkt; Ser473) (A) and phospho-glycogen synthase kinase (pGSK-3β; Ser9) (B) levels increased along with an increase in the number of NeuN–positive cells. Expression of phosphorylated-extracellular signal-regulated kinase (pERK) (C) and B-cell lymphoma 2 (Bcl-2) (D) increased and that of Bcl-2 associated X (Bax) (E) decreased with an increase in the number of SOX2–positive cells after GV1001 treatment, scale bar: 50 μm.